Plant Name: Humulus scandens
Taxonomic Information:
Plant ID: NPO6444
Plant Latin Name: Humulus scandens
Taxonomy Genus: Humulus
Taxonomy Family: Cannabaceae
Plant External Links:
NCBI TaxonomyDB:
228586
Plant-of-the-World-Online:
584308-1
Used in Medicines:
Unknown.
Geographical Distribution:
Italy; South Africa; France; United States; Belgium; Hungary
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| ADORA3; FFAR1; FFAR4; ADRA2B; | |
| GRM1; GRM8; | |
| TSHR; | |
| RECQL; HSD17B1; ALOX15; NOX4; POLB; | |
| ACHE; | |
| CDC25B; | |
| GRIA4; GRIA2; GRIK3; GRIK5; GRIK1; | |
| LCK; FLT3; MAPK1; MAPK14; FYN; CSNK2A1; | |
| POLA1; | |
| CA2; CA12; CA9; CA7; CA4; | |
| RORC; | |
| ESR2; | |
| NR1H4; | |
| MMP12; | |
| HIF1A; | |
| SLC1A1; | |
| LMNA; FABP3; FABP4; THPO; | |
| L3MBTL1; SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 5 | TBXAS1 | Thromboxane-A synthase | P24557 | CHEMBL1835 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Ionotropic glutamate receptor | GRIA4 | Glutamate receptor ionotropic, AMPA 4 | P48058 | CHEMBL3190 |
| Ionotropic glutamate receptor | GRIA2 | Glutamate receptor ionotropic, AMPA 2 | P42262 | CHEMBL4016 |
| Ionotropic glutamate receptor | GRIK3 | Glutamate receptor ionotropic kainate 3 | Q13003 | CHEMBL3684 |
| Ionotropic glutamate receptor | GRIK5 | Glutamate receptor ionotropic kainate 5 | Q16478 | CHEMBL2675 |
| Ionotropic glutamate receptor | GRIK1 | Glutamate receptor ionotropic kainate 1 | P39086 | CHEMBL1918 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
| Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 1 group F | RORC | Nuclear receptor ROR-gamma | P51449 | CHEMBL1741186 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Kinase | LCK | Tyrosine-protein kinase LCK | P06239 | CHEMBL258 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | MAPK14 | MAP kinase p38 alpha | Q16539 | CHEMBL260 |
| Protein Kinase | FYN | Tyrosine-protein kinase FYN | P06241 | CHEMBL1841 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Protein Phosphatase | CDC25B | Dual specificity phosphatase Cdc25B | P30305 | CHEMBL4804 |
| SLC superfamily of solute carriers | SLC1A1 | Excitatory amino acid transporter 3 | P43005 | CHEMBL2721 |
| Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Small molecule receptor (family A GPCR) | ADRA2B | Alpha-2b adrenergic receptor | P18089 | CHEMBL1942 |
| Small molecule receptor (family C GPCR) | GRM1 | Metabotropic glutamate receptor 1 | Q13255 | CHEMBL3772 |
| Small molecule receptor (family C GPCR) | GRM8 | Metabotropic glutamate receptor 8 | O00222 | CHEMBL3228 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transferase | POLA1 | DNA polymerase alpha subunit | P09884 | CHEMBL1828 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 2.509E-10 | 1.366E-06 | CA12, CA2, CA4, CA7, CA9 |
| MF | GO:0005215; transporter activity | GO:0005234; extracellularly glutamate-gated ion channel activity | 9.640E-10 | 1.880E-06 | GRIA2, GRIA4, GRIK1, GRIK3, GRIK5 |
| BP | GO:0009987; cellular process | GO:0035235; ionotropic glutamate receptor signaling pathway | 5.382E-09 | 8.370E-06 | GRIA2, GRIA4, GRIK1, GRIK3, GRIK5 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 3.026E-08 | 3.661E-05 | CA12, CA2, CA4, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 8.586E-08 | 7.396E-05 | CA12, CA2, CA4, CA7, CA9 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 9.641E-08 | 7.775E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, NOX4 |
| MF | GO:0005215; transporter activity | GO:0015277; kainate selective glutamate receptor activity | 1.529E-07 | 1.040E-04 | GRIK1, GRIK3, GRIK5 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 3.123E-07 | 1.744E-04 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
| MF | Unclassified; | GO:0004872; receptor activity | 7.475E-07 | 3.191E-04 | ADORA3, ADRA2B, ESR2, FFAR1, FFAR4, FLT3, GRIA2, GRIA4, GRIK1, GRIK3, GRIK5, GRM1, GRM8, NR1H4, RORC, TSHR |
| BP | GO:0023052; signaling | GO:0060079; excitatory postsynaptic potential | 8.473E-07 | 3.332E-04 | GRIA2, GRIA4, GRIK1, GRIK3, GRIK5 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 8.333E-07 | 3.332E-04 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, NOX4, TBXAS1 |
| BP | GO:0009987; cellular process | GO:0007196; adenylate cyclase-inhibiting G-protein coupled glutamate receptor signaling pathway | 1.275E-06 | 4.549E-04 | GRIK3, GRM1, GRM8 |
| BP | GO:0050896; response to stimulus | GO:0033993; response to lipid | 1.468E-06 | 4.930E-04 | CA2, CA9, CSNK2A1, CYP1A1, CYP1A2, FABP3, FFAR1, FLT3, MAPK14, NR1H4, RORC |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.818E-06 | 5.822E-04 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 3.063E-06 | 9.394E-04 | ALOX15, CYP19A1, CYP1A1, CYP1A2, CYP1B1, TBXAS1 |
| MF | GO:0005488; binding | GO:0042610; CD8 receptor binding | 6.304E-06 | 1.634E-03 | FYN, LCK |
| CC | GO:0044464; cell part | GO:0043204; perikaryon | 1.060E-05 | 2.430E-03 | GRIK3, GRIK5, MAPK1, SMN1, SMN2 |
| BP | GO:0023052; signaling | GO:0051966; regulation of synaptic transmission, glutamatergic | 1.501E-05 | 3.204E-03 | GRIK1, GRIK3, GRM1, GRM8 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.888E-05 | 3.953E-03 | CA2, CA7 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.976E-05 | 4.039E-03 | CYP1A1, CYP1A2, CYP1B1 |
| CC | GO:0044464; cell part | GO:0043005; neuron projection | 2.519E-05 | 4.812E-03 | CA2, FYN, GRIA2, GRIA4, GRIK3, GRIK5, GRM1, MAPK1, SMN1, SMN2 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 2.622E-05 | 4.857E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0009987; cellular process | GO:0050714; positive regulation of protein secretion | 2.747E-05 | 4.984E-03 | ACHE, FFAR1, HIF1A, MAPK14, MMP12, NR1H4 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 3.050E-05 | 5.357E-03 | CA12, CA2, CA4, CA7, CA9, ESR2, L3MBTL1, MMP12, NR1H4, RORC |
| BP | GO:0009987; cellular process | GO:0055082; cellular chemical homeostasis | 3.382E-05 | 5.844E-03 | CA2, CA7, GRIK5, GRM1, HIF1A, LCK, MAPK1, NOX4, NR1H4 |
| BP | GO:0050896; response to stimulus | GO:0009725; response to hormone | 3.632E-05 | 6.083E-03 | CA2, CA9, CSNK2A1, CYP1A2, FABP3, FFAR4, FLT3, FYN, TSHR |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 3.770E-05 | 6.173E-03 | CYP1A1, CYP1A2 |
| MF | GO:0005215; transporter activity | GO:0004971; AMPA glutamate receptor activity | 3.770E-05 | 6.173E-03 | GRIA2, GRIA4 |
| MF | GO:0005488; binding | GO:0005504; fatty acid binding | 4.299E-05 | 6.833E-03 | FABP3, FABP4, FFAR4 |
| BP | GO:0009987; cellular process | GO:0007188; adenylate cyclase-modulating G-protein coupled receptor signaling pathway | 4.613E-05 | 7.073E-03 | ADRA2B, GRIK3, GRM1, GRM8, TSHR |
| BP | GO:0065007; biological regulation | GO:0042593; glucose homeostasis | 5.051E-05 | 7.482E-03 | FFAR1, GRIK5, HIF1A, NOX4, NR1H4 |
| BP | GO:0002376; immune system process | GO:0045639; positive regulation of myeloid cell differentiation | 6.660E-05 | 9.343E-03 | CA2, HIF1A, MAPK14, THPO |
| BP | GO:0008152; metabolic process | GO:0046486; glycerolipid metabolic process | 6.693E-05 | 9.343E-03 | ACHE, ALOX15, CSNK2A1, FABP3, FABP4, FYN, LCK |
| MF | GO:0005488; binding | GO:0005496; steroid binding | 6.660E-05 | 9.343E-03 | ESR2, HSD17B1, NR1H4, RORC |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09150 Organismal Systems | 09156 Nervous system | hsa04724 | Glutamatergic synapse | 7.823E-12 | 1.158E-09 | GRIA2, GRIK5, SLC1A1, GRM8, GRIK3, MAPK1, GRIK1, GRM1, GRIA4 |
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 1.128E-09 | 5.563E-08 | GRIA2, GRIK5, ADORA3, GRM8, GRIK3, GRIK1, ADRA2B, TSHR, GRM1, GRIA4 |
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 4.331E-10 | 3.205E-08 | CA12, CA2, CA4, CA7, CA9 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 2.974E-07 | 1.101E-05 | HSD17B1, CYP1A2, CYP1A1, CYP1B1, CYP19A1 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04723 | Retrograde endocannabinoid signaling | 4.752E-06 | 1.407E-04 | GRIA2, MAPK1, MAPK14, GRM1, GRIA4 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 6.739E-06 | 1.662E-04 | HSD17B1, CYP1A1, CYP1B1, CYP19A1 |
| 09150 Organismal Systems | 09151 Immune system | hsa04660 | T cell receptor signaling pathway | 1.221E-04 | 2.370E-03 | LCK, MAPK1, FYN, MAPK14 |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 1.281E-04 | 2.370E-03 | CYP1A2, CYP1A1, CYP1B1 |
| 09150 Organismal Systems | 09151 Immune system | hsa04611 | Platelet activation | 2.258E-04 | 3.342E-03 | TBXAS1, MAPK1, FYN, MAPK14 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04071 | Sphingolipid signaling pathway | 2.120E-04 | 3.342E-03 | ADORA3, MAPK1, FYN, MAPK14 |
| 09150 Organismal Systems | 09158 Development | hsa04380 | Osteoclast differentiation | 3.052E-04 | 4.106E-03 | LCK, MAPK1, FYN, MAPK14 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04072 | Phospholipase D signaling pathway | 4.246E-04 | 4.880E-03 | GRM8, MAPK1, FYN, GRM1 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04730 | Long-term depression | 4.287E-04 | 4.880E-03 | GRIA2, MAPK1, GRM1 |
| 09150 Organismal Systems | 09151 Immune system | hsa04664 | Fc epsilon RI signaling pathway | 6.192E-04 | 5.728E-03 | MAPK1, FYN, MAPK14 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04720 | Long-term potentiation | 5.674E-04 | 5.728E-03 | GRIA2, MAPK1, GRM1 |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 5.929E-04 | 5.728E-03 | FLT3, MAPK1, HIF1A |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 7.319E-04 | 6.175E-03 | MAPK1, MAPK14, ESR2 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 1.420E-03 | 9.685E-03 | GRIA2, MAPK1, TSHR, GRIA4 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 7.619E-04 | 6.175E-03 | CYP1A2, CYP1A1, CYP1B1 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 7.928E-04 | 6.175E-03 | CSNK2A1, MAPK1, FYN |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 1.068E-03 | 7.905E-03 | CYP1A2, CYP1A1, CYP1B1 |
| 09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 1.440E-03 | 9.685E-03 | CA2, CA4 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2; |
| I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3; |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
| I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | TBXAS1; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| NA: NA | Hepatitis C virus infection | NA | ADORA3; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | GRM1; ACHE; |
| C00-D49: Neoplasms | AML | NA | FLT3; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MMP12; MAPK14; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| NA: NA | Edema | NA | CA2; |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
| C00-D49: Neoplasms | CLL | NA | FLT3; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; |
| NA: NA | Acute respiratory distress syndrome | NA | MAPK14; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
| I00-I99: Diseases of the circulatory system | Coronary artery disease | I20-I25 | MAPK14; |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | GRIK1; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; |
| I00-I99: Diseases of the circulatory system | Thromboembolism | I80-I82 | TBXAS1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; ADORA3; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | MAPK14; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | ADORA3; |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
| H00-H59: Diseases of the eye and adnexa | Diabetic retinopathy | H36, E10.3, E11.3, E13.3 | MAPK14; |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3; |
| N00-N99: Diseases of the genitourinary system | Nephritis | N00-N19, N25-N29 | TBXAS1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Huntington's disease | F02.2, G10 | GRM1; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; CA2; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
| I00-I99: Diseases of the circulatory system | Acute coronary syndrome | I74 | MAPK14; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | LCK; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | MMP12; TBXAS1; |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | MMP12; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | FLT3; |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; GRIA2; GRIA4; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | GRM1; ACHE; GRIK1; |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | MAPK14; TBXAS1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ADORA3; |
| NA: NA | Inflammatory diseases | NA | MAPK14; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MMP12; MAPK14; |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | TBXAS1; FFAR1; |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9; |
| A00-B99: Certain infectious and parasitic diseases | Viral infections | B01, B02, A60, B00, B27, G05.1, P35.2 | POLA1; |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; MAPK14; |
| NA: NA | GIST | NA | FLT3; |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1; |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | GRM1; ADRA2B; GRIK1; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | GRM1; GRIK1; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | TBXAS1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1; |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | FLT3; |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | GRM1; |
| C00-D49: Neoplasms | Breast cancer | C50 | FLT3; CYP19A1; CA9; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | ADRA2B; GRIK1; |
| J00-J99: Diseases of the respiratory system | Acute lung injury | J80 | MAPK14; |
| NA: NA | Rheumatold arthritis | NA | MAPK14; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | MAPK14; |
| C00-D49: Neoplasms | Cancer | C00-C96 | CSNK2A1; FLT3; ACHE; HIF1A; ADORA3; MAPK1; MAPK14; CDC25B; CA9; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | FLT3; HIF1A; MAPK1; CA9; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | FFAR1; |
| I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | TBXAS1; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
